<SUBMISSION>
<ACCESSION-NUMBER>0001104659-03-011781
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20030604
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030605
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CERUS CORP
<CIK>0001020214
<ASSIGNED-SIC>2836
<IRS-NUMBER>680262011
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-21937
<FILM-NUMBER>03733940
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>2411 STANWELL DR
<CITY>CONCORD
<STATE>CA
<ZIP>94520
<PHONE>9252886000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>2525 STANWELL DRIVE
<STREET2>STE 300
<CITY>CONCORD
<STATE>CA
<ZIP>94520
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CERUS TECHNOLOGIES INC
<DATE-CHANGED>19960731
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>j1819_8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>

<head>

<title>  </title>

</head>

<body>

<div style="font-family:'Times New Roman';">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to
Section 13 or 15(d) of the<br>
Securities Exchange Act of 1934</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Date
of Report (Date of earliest event reported):&#160;
June 4, 2003</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CERUS
  CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant
  as specified in its charter)</font></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.74%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-21937</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.74%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">68-0262011</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State of
  jurisdiction)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File
  No.)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.74%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer
  Identification No.)</font></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.74%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2411
  Stanwell Drive<br>
  Concord, California 94520</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of
  principal executive offices and zip code)</font></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.48%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.74%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code: <b><font style="font-weight:bold;">(925)
  288-6000</font></b></font></p>
  </td>
 </tr>
</table>

</div>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\C2\tsauer\1819_1\t_1609483\j1819_8k.htm',USER='tsauer',CD='Jun  4 17:53 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.&#160; Other Events.</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June 4, 2003, Cerus
Corporation (the &#147;Company&#148;) and Baxter International, Inc. (&#147;Baxter&#148;) announced
that the Company and Baxter reached agreement with the U.S. Food and Drug
Administration on steps for regulatory approval for their pathogen inactivation
system for platelets.&#160; A copy of the
Company&#146;s press release is attached as Exhibit 99.1 hereto and is incorporated
herein by reference.</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 7.&#160; Exhibits.</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="9%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:9.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="82%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:82.36%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description
  of Exhibit</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="82%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:82.36%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release,
  dated June 4, 2003, entitled &#147;Baxter and Cerus Reach Agreement With FDA On
  Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation
  System.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='2',FILE='C:\C2\tsauer\1819_1\t_1609483\j1819_8k.htm',USER='tsauer',CD='Jun  4 17:53 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</font></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="51%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:51.66%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.76%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.76%;">
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:</font></p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June 4, 2003</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="31%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:31.62%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;/s/&#160; Gregory W. Schafer</font></p>
  </td>
  <td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.14%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.76%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gregory W.
  Schafer</font></p>
  </td>
 </tr>
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.56%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.78%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.9%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.76%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,
  Finance and<br>
  Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>


<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='3',FILE='C:\C2\tsauer\1819_1\t_1609483\j1819_8k.htm',USER='tsauer',CD='Jun  4 17:53 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Index to Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="9%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:9.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="82%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:82.36%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description
  of Exhibit</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.0%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p align="left" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:left;">&nbsp;</p>
  </td>
  <td width="82%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:82.36%;">
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release,
  dated June 4, 2003, entitled &#147;Baxter and Cerus Reach Agreement With FDA On
  Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation
  System.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>


<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>


<!-- SEQ.=1,FOLIO='4',FILE='C:\C2\tsauer\1819_1\t_1609483\j1819_8k.htm',USER='tsauer',CD='Jun  4 17:53 2003' -->
</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>j1819_ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>

<head>

<title>  </title>

</head>

<body>

<div style="font-family:'Times New Roman';">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="168" height="34" src="j1819ex99d1image002.gif"></font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.64%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="144" height="37" src="j1819ex99d1image003.gif"></font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Cerus</font></u></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Baxter</font></u></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Media and Investor
  Relations:</font></i></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Media:</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sylvia Wheeler, (925) 288-6061</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tanya Tyska, (847) 270-4918, North America</font></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lisa Luttinger, (925)
  288-6036</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jed Weiner, (847) 270-3928, North America</font></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patty O&#146;Hayer, 32 2 650 1924, Europe</font></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investor
  Relations:</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neville Jeharajah, (847) 948-2875</font></p>
  </td>
 </tr>
 <tr>
  <td width="41%" valign="top" style="padding:0in .7pt 0in .7pt;width:41.68%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.1%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="55%" valign="top" style="padding:0in .7pt 0in .7pt;width:55.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mary Kay Ladone, (847) 948-3371</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BAXTER AND CERUS REACH AGREEMENT WITH FDA</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ON STEPS TO GAIN REGULATORY APPROVAL</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR INNOVATIVE PATHOGEN INACTIVATION SYSTEM</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DEERFIELD, ILL. and CONCORD, CALIF.<i><font style="font-style:italic;">,
</font></i>June 4, 2003&#151;Subsidiaries of Baxter International Inc. (NYSE: BAX)
and Cerus Corporation (Nasdaq: CERS) announced today that the companies reached
agreement with the U.S. Food and Drug Administration (FDA) on steps for
regulatory approval for their pathogen inactivation system for platelets.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter and Cerus have been in ongoing discussions with the FDA
throughout the submission of their modular application for their pathogen
inactivation system for platelets.&#160; The
steps that have been agreed upon include conducting a supplemental platelet
transfusion study and performing additional analysis of the U.S. Phase III
clinical trial data.&#160; The clinical trial
will be carried out using the commercial set and will provide additional data
to address FDA questions related to platelet performance in the U.S. Phase III
clinical trial.&#160; This commercial set has
previously undergone successful European clinical testing and is now
commercially available in Europe.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are pleased to have reached this agreement, and with these two
additional steps we now have a clear path to complete the regulatory submission
process,&#148; said Stephen T. Isaacs, president and chief executive officer of
Cerus.&#160; &#147;Our resolve is strong to make
the blood supply as safe as possible and we are committed to moving
expeditiously to bring this innovative technology to the marketplace.&#148;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-more-</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\C2\lsmith\1819_3\t_1610002\j1819_ex99d1.htm',USER='lsmith',CD='Jun  4 19:52 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Greg Young, corporate vice president and president of Baxter&#146;s
Transfusion Therapies business said,&#160;
&#147;We continue to work collaboratively with the FDA throughout this
process, and accept the responsibility that comes with being leaders looking to
bring an innovative critical care therapy to the marketplace.&#160; Baxter and Cerus are dedicated to taking all
necessary steps required by the FDA to definitively demonstrate that our
pathogen inactivation system will offer an additional layer of safety to the
nation&#146;s blood supply.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The two companies expect to complete the additional steps in the next
15-18 months with regulatory submission to follow shortly thereafter.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Baxter and Cerus&#146; pathogen
inactivation system </font>is being developed to potentially protect
patients by reducing the risk of transfusion-transmitted diseases.&#160; The system is designed to go a step beyond
current blood safety measures, which <i><font style="font-style:italic;">test</font></i>
for certain infectious diseases, by <i><font style="font-style:italic;">inactivating</font></i>
a broad spectrum of pathogens, including viruses, bacteria, parasites and
potentially harmful donor white blood cells in blood components intended for
transfusion.&#160; </font>For platelets, the system uses a
light-activated compound that is designed to target and inactivate pathogens
containing DNA and RNA, such as HIV and hepatitis B and C, and to render them
harmless by preventing them from replicating.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">In 2002 the companies received
regulatory approval in Europe for the technology, known as the </font>INTERCEPT
Blood System for platelets.&#160; The
INTERCEPT Blood System is the only pathogen inactivation system that is
approved and available for use in Europe with platelets. </font>Patients undergoing chemotherapy,
heart bypass surgery and other procedures that require platelet transfusions
are expected to benefit from this technology.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus and Baxter are conducting clinical trials of their pathogen
inactivation system for use with plasma and red blood cells for transfusion,
making their system the only pathogen inactivation technology currently being
developed for use with all primary blood components.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter International Inc. assists health-care professionals and their
patients with treatment of complex medical conditions, including cancer,
hemophilia, immune disorders, kidney disease</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='2',FILE='C:\C2\lsmith\1819_3\t_1610002\j1819_ex99d1.htm',USER='lsmith',CD='Jun  4 19:52 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and trauma. The company applies its expertise in medical devices,
pharmaceuticals and biotechnology to make a meaningful difference in patients&#146;
lives. For more information about Baxter, please visit www.baxter.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation is developing medical systems and therapeutics to
provide safer and more effective options to patients. The company is developing
products based on its proprietary Helinx&#174; technology for controlling biological
replication. Cerus&#146; most advanced programs are focused on systems to enhance
the safety of the world&#146;s blood supply. The INTERCEPT Blood System, which is
being developed in collaboration with subsidiaries of Baxter International Inc.
is based on the company&#146;s Helinx technology.&#160;
The Concord, California-based company also is pursuing therapeutic
applications of Helinx technology to treat and prevent serious diseases.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Helinx </font>is a U.S. registered
trademark of Cerus Corporation.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter and INTERCEPT Blood are
trademarks of Baxter International Inc.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Statements in this news release regarding
regulatory filings, product development and commercial potential are
forward-looking statements that involve risks and uncertainties.&#160; Actual results could differ materially from
the above forward-looking statements as a result of certain factors, including
the risks and uncertainty of the timing and results of clinical trials and
other development activities, actions by regulatory authorities at any stage of
the development and commercialization process, additional financing activities,
manufacturing, market acceptance of any products, competitive conditions and
other factors discussed in the companies&#146; most recent filings with the
Securities and Exchange Commission.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"># # #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>


<!-- SEQ.=1,FOLIO='3',FILE='C:\C2\lsmith\1819_3\t_1610002\j1819_ex99d1.htm',USER='lsmith',CD='Jun  4 19:52 2003' -->
</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>j1819ex99d1image003.gif
<DESCRIPTION>J1819EX99D1IMAGE003.GIF
<TEXT>
begin 644 j1819ex99d1image003.gif
M1TE&.#EAD``E`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'_
M"TU33T9&24-%.2XP&`````QM<T]035-/1D9)0T4Y+C!`:4N4*@`A_PM-4T]&
M1DE#13DN,!4````)<$A9<P```$````!``&)#8UL`(?\+35-/1D9)0T4Y+C`8
M````#&-M4%!*0VUP,#<Q,@````-(`'.\`"'Y!`$`````+`````"0`"4`A8&!
M@0`S9@`SF0!F9@!FF3,S9C,SF3-F9C-FF68SF69FF69FS&:9F6:9S)EFF9EF
MS)F9F9F9S)G,S+N[N\R9S,S,S-W=W<S,_\S_S,S____,S/_,____S.[N[O__
M_P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P;_0(]P6#$8$,9C4FE$-A&5H71*K5JOV*QVR]4"J!=$X5A`
ME@T'8_J<-D:[\+A\3J]^IT6G&:EGMI$*=8*#A(-W4A5B9$QL1F=*!0)OA915
M'1<=E8*'0Q$"2DYM!F-H36-\$9J4%1(1$0JP"A*J=)Q""HUG#`VNO'Q*;1"T
M@Q<!CDR3PUVV'DY-21-XH\]'J<IT$:!D"!?7<+8;?(U05$=[8[/><@UC:T[J
MR])ZIP941?1DW?!='`I,2`<"[?,R1<(H14X49)(BX5>I>D(D4)!0(0*KB1<I
M2J2H;\B&C14S)L.S<:('/TED16CE:E*&"B%!RL1(A:)%D!Y>WL1H2T&?_U(,
MJ$1HQR2HAPNDEBA56F:DOZ5&%DI;4@'I(H>DTJ2KD.`35*@*)FT`>P&74@0]
MGSVR)L6?DU,"\Y021W>ND8X>*@@`N,U`NBD^R<PRV&>--@-1PFA+(X8OWR,=
M$3`NI8#!,SX+.&5PK`9QN<:0TEE&:43`'[4(!`K)<)#:@053.CQ-8VWHPSZ/
M$&2"<)`>`J^A@!DPROHJ**+H.%TX?88;'E)[#.B#E;JZSU@($-([@)?WHC;<
MI2SXQ38P)#[9T:3VT,%AFP(^LY\1D!1B(GQFFGQ"4H%3D=L'P<1*599%9X!`
M'535008;9+#@@@QFX)8I;DBQ'#5.I-.!=P<((/_,$-'ILD%5&EQ@03?_Y3;<
M!3!=P!MZ9UC@03;?/6$=&AYP,M0\3"SQ5G!_;5$!>,^,M$`CE&62C2(19"!$
M)O@9P18>#BF23'$(51A!EDI4T,$&'*"8"B>SH697<Z!$(-46-`9'#D/'.(-8
M-HRI)H1>BH"'EQ01&`,:9%)8<%L[W4QX!GQ7<%*EBG^^AX":<;!CH'14'%!7
M&O$9H8"3<&)8P!43FJ(;(A0Z$45^>C20Z!`7`MAA4NX98=23$E#GSZVV)C&9
MI54\L)>ND*`!&Q5NC7-%=&W8.6-NIQPU61ECC"3%(?\%IVEVZ8V!IF>9_)<$
M<I]`*XZF561PRK9\2.O_0:@)72&<$E-ZT$"I1^1U69>K1M07&9LVJ,%+OQ"%
MX#;H]OA/`:I6\51^?ZPIQ4-_Q$O$H.;$HD`#N/`8%)W3'(3%(;8YPH>RZ_K6
M1$3T_'J$,41IAX3$$;GS#\P>8-!9:%8TA&''^=&;RFB_(/'QDVXYY!<5XX*2
M2;'?*;#`=3^I<0$'58S%8QH?VK/?;7MV<FYT??QIY;HAKI=O>^>4(NW!I>2$
M$A()#Q%88V=T/42!4=J=S2-*4*TP(P$C8$P:^_DI0#=<OCST4=/\A,%4DP%B
M+SYCR-A6XZ!@46UK9<!L7AJ8'MN:'M?9:G$L]J8MR>)#:G.&/=N.H:IWG''Z
M_^2B!UIRBW%*D-S,/[):P0'P8T#@9#><.IA!A$YNSI>Z0]SAR323D3POYHJ;
M9XJRK9Z6]102'JS=2!VT%K$5]V2)``5=>"(*'UG<,:&<LPYQ)%W1_BYN\*3^
MTD:0[!'"BXB2!"?$30@V<X885E<%PERE`':SPF@8TZS%/09T1Y-">WJ4KM]5
M*5XA:PX$J="!T8AO=!H@%9+>)!0?G:P+[.+?JLH7-B-(8`-3NX`&"$/`-`CA
M,="*5X$X6(4V!>!BIU%$!N^TLQ$6,1=(>-P6RG>N4M`L>I/K&::L\R-M"`1X
MP>M`)A33"%YI<$ND4`"+>"<Y(NSE:TN<PKS0E<(K4/^M6V",HQT\P,/#R,DN
M;S%`PH"VOP,=P2Q_,H`#"N(;*2X,CLDHX!+4^*\-8(!%"6($&1I0%0%YLI-1
MJ,``;I8&Z&%Q8:6`EC8"N;]T[$B2DZ'&,PCPETR"8A(.!-Z4)&.^@YPN$!<*
MV&4F%*I9+*`S>G`8%;[@CUA>;72KK./O*.BC<:AR$HE81#(LD#9W.`F/P*N2
M`6I#O<6X$!0;()MK#*#,*0``3R*[V4^>=81D5$N$&?H)$K82)VF9YR?1D!O=
M%N&'=$B(1[!$32#,5:,CM'-:J#10ENB9'6E5X"G'R5TS;[;(<*3IB>_"E%0R
MT*9GR*PC'=B2'J@Y+L7)!7@<#XT>`&9*TYK:]*8XS:E.=\K3GOKTIT`-:DZ#
#```[
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>j1819ex99d1image002.gif
<DESCRIPTION>J1819EX99D1IMAGE002.GIF
<TEXT>
begin 644 j1819ex99d1image002.gif
M1TE&.#EAJ``B`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````J``B`(8````S``!F``"9````,P`S,P!F,P"9,P```#,S`#-F`#.9`#,`
M,S,S,S-F,S.9,S/,,S,S9C-F9C/,9C,S,V9F,V:9,V;,,V8S9F9F9F:99F;,
M9F9FF6:9F6:99IG,9IEFF9F9F9G,F9F9S)G,S)EF9IF9F<S,F<S_F<R9S,S,
MS,S_S,S,_\S__\S,S/__S/_,______\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,&_\"8<$@4&E[%I'+)
M;#J?T*AT2JT2!0J!=<OM>K_@ID,P4"S"Z+1ZW;T(Q@+#`ZT*A41VDWUO>K92
M>X%V>$A#@H%Z@B.%2RL@@2=/CX,@32$9$I@8&9R:FA(8(4P;`F18I1M=*@T`
MK:ZOKP1,&0&PMJZB0[>[L!U*);"R3K9*(+S'!4LGI0IP90HB6\>W"4H1T[:Y
M0@78O$G&KPA/Q$7=NPU**V\'I6]QI2A4(>:P2?2OVC&U]_5$';#BAO73Q>\5
MNB3MLKB+D\7`%!(%6Y6+F"]B+"+@7%43^(I(!HNM#A(9X,``%I-DLB@HHR4*
M+P(,&LB<.=,!D02[$`#@AH```?^=!`(@B#1DWS2=N_P%&S<P!B\&0FO]+*"3
M)P`,11ZT.Z"2JTF38VP^866KPA05MPBHH(+450HF+KC!RC#$`ZR-3<C%6'&K
MCQ4+IQ0H,+G`@,HR!A8(,,L1'Q4&MH11D>O*@Q/(KQC'^!>.:4<A\V!9MB)"
M`#N4`]Z5@M-.P(<F'V$EHW)KB]%6^90XD#TD8RO)3/0":THE\."5"A<X2.UU
M<,LE.&&MG3+"EH0M;5M5:E)A*6A8`3R[&A+[<Q4+J0>P4VSR0.'565@JF!!<
MKY3NL%Q@%WT9EDC.K@"WA%X`NK*"%:MAX9Q*S"C&#$K/V<,;%;=)M`4!L.0F
MX2LE].;_75X#M7#+6U.(D`5[S)2"TE?.D52*AC&@!0M65&`(4C0$O8(!'H=P
M@!DL!PI1(`!XU6>>4_<0D$`$^6B@(G)@L02'0@R:H82,'%8!$FY$;`E`>'79
M-V!3^$6D@1"%.<A0:H-)F9H!8WPU0#&VX#B%E_E4R$\+&`$DGH4Y1D27E(8]
M:9)S[IQ8J`*,##$D`"-HN66D@19$0A%V7=08H$/\6%`,"K&DIHHG)?B@`'P6
M41TLE-ZY93XV\B.24J^`">*10Y#@*3T5&.`B6(DE-L9*I:9IF@`P),$7+&?2
M)N84>F)C9Q%#,O`G`$ZH\`(++ZP`@PLPJ-#!KE\RJ"9+9$39_\ZB`C1:*0":
M24$N%[MJ2-EX=+Y2Y)BX.@M+G`E.66@[89&J`+^N6$N%!+80546%VTWTRFR8
M?F@DOEMH8`M@#3W)3DH0,H/N$O-2@:4KLTZQJR]),`QD$A`1EX0)STY1GBND
M'$KEJ2N%A5@I%RP1VBO7^=MO%!7"B.0K"DOL"@M-D'6T%'K"$$=J#+WAX@"&
M^;KF&-,I<8O23&!P2Y"NOC):$H]J:$M`"(?$Q:/).""8K\2FR-IA6!S0Q*,`
M$""!!X?8,8(=7=Z"@`1W%&Z'?D/<"T#$263'J1!2'YW"V$2H4$`#G]-$4TRQ
MSKA70G'8?;5");U9RJ5-1-L-$3$75.U1ADRP8(M80[RP2P`)R&0YKIMOF2K'
M[!!;Z`'+J928`A!`4;HY30NA<4&M+EU9$R43428_)`YQPI:SLF-WH8HQF%ZZ
M4E#P:1$GFS-M-IM>'D/FYJP]1/$143Q$.ZF)TX(,,RQW/8%<QUC"S;!Q.[4Y
MP66.*<+0L,&`5!5A?`4)@-(.$("%".`]"SG#%D0@`;(@@!L82D!/`E"])+@@
M`Q1(`$ZFLL(3`L!A]RL`"P&`@&D-:(>U\%_G'#"]5B`@`1F`VA(\)[K0-;$"
E%2#;$#Y0BI\M1`'-8H,6M\A%,)#``L,RC05\V,4RFO&,00``.S\_
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
